Journey Medical Q2 EPS Forecast Decreased by Roth Capital

Journey Medical Co. (NASDAQ:DERM) – Research analysts at Roth Capital dropped their Q2 2025 earnings per share estimates for Journey Medical in a research report issued on Thursday, May 15th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of ($0.02). The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical’s Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.03 EPS and FY2025 earnings at ($0.23) EPS.

DERM has been the topic of a number of other reports. Alliance Global Partners restated a “buy” rating on shares of Journey Medical in a report on Thursday. Industrial Alliance Securities set a $10.50 price target on Journey Medical in a report on Thursday, March 27th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $9.88.

Journey Medical Price Performance

Journey Medical stock opened at $6.75 on Monday. The stock has a market capitalization of $155.95 million, a price-to-earnings ratio of -7.18 and a beta of 0.86. Journey Medical has a 52-week low of $3.20 and a 52-week high of $8.24. The stock’s 50 day moving average price is $6.47 and its two-hundred day moving average price is $5.42. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38.

Journey Medical (NASDAQ:DERM) last announced its earnings results on Wednesday, May 14th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.06. The business had revenue of $13.14 million for the quarter, compared to analysts’ expectations of $12.05 million. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of DERM. Dimensional Fund Advisors LP bought a new position in Journey Medical in the 4th quarter valued at $80,000. Kovitz Investment Group Partners LLC grew its stake in shares of Journey Medical by 112.9% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock worth $97,000 after acquiring an additional 13,105 shares during the period. Citadel Advisors LLC bought a new position in shares of Journey Medical during the 4th quarter worth $174,000. Cetera Investment Advisers grew its stake in shares of Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock worth $54,000 after acquiring an additional 2,478 shares during the period. Finally, Tang Capital Management LLC bought a new position in shares of Journey Medical during the 4th quarter worth $6,747,000. Institutional investors own 7.25% of the company’s stock.

Insider Transactions at Journey Medical

In related news, CEO Claude Maraoui sold 14,905 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.01, for a total value of $74,674.05. Following the completion of the sale, the chief executive officer now directly owns 2,052,418 shares of the company’s stock, valued at approximately $10,282,614.18. This represents a 0.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 113,522 shares of company stock valued at $589,229 over the last ninety days. 15.03% of the stock is owned by company insiders.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.